Repligen (RGEN) announced the launch of three new high-performance chromatography resins: AVIPure HiPer AAV9 and AVIPure HiPer AAV8 affinity resins, along with HiPer QA anion exchange resin, expanding the company’s growing proteins portfolio and reinforcing its commitment to innovation in next-generation bioprocessing. As momentum continues across new modalities, Repligen remains focused on providing customers with the cutting-edge tools they need. These new resins extend the company’s leadership in process productivity and strengthen its portfolio ahead of broader chromatography resin launches anticipated in 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen price target raised to $190 from $175 at Wells Fargo
- Repligen price target raised to $200 from $175 at Barclays
- Repligen’s Q3 Earnings Call: Strong Growth and Positive Outlook
- Repligen price target raised to $165 from $150 at Canaccord
- Repligen price target raised to $175 from $160 at Barclays